Matches in SemOpenAlex for { <https://semopenalex.org/work/W4353074429> ?p ?o ?g. }
- W4353074429 endingPage "805" @default.
- W4353074429 startingPage "793" @default.
- W4353074429 abstract "To quantify the preferences of people with type 2 diabetes (T2D) for treatment attributes of a glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist (RA) versus an injectable GLP-1 RA medication profile.Injection-naive people taking oral medications for T2D in the US and UK completed a web survey including a discrete choice experiment to quantify patients' preferences for five treatment attributes: delivery system, frequency of nausea, frequency of hypoglycemia, HbA1c reduction, and weight reduction. Attributes and levels were based on head-to-head clinical trial data of tirzepatide 5mg, 10mg, and 15mg versus semaglutide 1mg. Preference data were analyzed separately by country using multinomial mixed logit (MXL) models. MXL parameters were used to estimate the predicted preference for each tirzepatide dose versus semaglutide 1mg. Direct preferences for each dose of tirzepatide versus semaglutide 1mg were elicited.Participants (N=620) in the US (N=301) and UK (N=319) were 50.8% and 50.5% female with mean ages of 60.7 years and 58.9 years, respectively. The order and magnitude of relative attribute importance (RAI) scores differed between countries. HbA1c reduction (26.3%) had the greatest impact on US participants' preferences, and hypoglycemia (32.8%) did among UK participants. Attribute-level marginal utility results indicated preferences for greater HbA1c improvements, the single-use pre-filled pen, lower hypoglycemia, greater weight reductions, and lower frequency of nausea. Assuming the availability of only tirzepatide or semaglutide 1mg, the predicted preference for tirzepatide (5, 10, and 15mg) in the US is 95.6% (vs 4.4% for semaglutide 1mg) and in the UK was 86.3% (vs 13.7% for semaglutide 1mg).HbA1c reduction, frequency of hypoglycemia, and weight reduction are key drivers of preferences among people with T2D when considering medication options. Overall, people with T2D are likely to prefer the tirzepatide over the semaglutide 1mg medication profiles." @default.
- W4353074429 created "2023-03-23" @default.
- W4353074429 creator A5013568217 @default.
- W4353074429 creator A5029551157 @default.
- W4353074429 creator A5035168684 @default.
- W4353074429 creator A5039006946 @default.
- W4353074429 creator A5039792370 @default.
- W4353074429 creator A5073954474 @default.
- W4353074429 creator A5075264835 @default.
- W4353074429 date "2023-03-01" @default.
- W4353074429 modified "2023-09-30" @default.
- W4353074429 title "The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes" @default.
- W4353074429 cites W1988255364 @default.
- W4353074429 cites W2011998736 @default.
- W4353074429 cites W2015901745 @default.
- W4353074429 cites W2096416969 @default.
- W4353074429 cites W2107680428 @default.
- W4353074429 cites W2478113780 @default.
- W4353074429 cites W2532555978 @default.
- W4353074429 cites W2765781150 @default.
- W4353074429 cites W2894431684 @default.
- W4353074429 cites W2895666357 @default.
- W4353074429 cites W2920836114 @default.
- W4353074429 cites W2938716486 @default.
- W4353074429 cites W3110313641 @default.
- W4353074429 cites W3164789813 @default.
- W4353074429 cites W3177122952 @default.
- W4353074429 cites W3191712049 @default.
- W4353074429 cites W3205201678 @default.
- W4353074429 cites W4213140092 @default.
- W4353074429 cites W4229060143 @default.
- W4353074429 cites W4289712133 @default.
- W4353074429 cites W4296802076 @default.
- W4353074429 cites W4311264067 @default.
- W4353074429 doi "https://doi.org/10.2147/ppa.s401465" @default.
- W4353074429 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36987498" @default.
- W4353074429 hasPublicationYear "2023" @default.
- W4353074429 type Work @default.
- W4353074429 citedByCount "0" @default.
- W4353074429 crossrefType "journal-article" @default.
- W4353074429 hasAuthorship W4353074429A5013568217 @default.
- W4353074429 hasAuthorship W4353074429A5029551157 @default.
- W4353074429 hasAuthorship W4353074429A5035168684 @default.
- W4353074429 hasAuthorship W4353074429A5039006946 @default.
- W4353074429 hasAuthorship W4353074429A5039792370 @default.
- W4353074429 hasAuthorship W4353074429A5073954474 @default.
- W4353074429 hasAuthorship W4353074429A5075264835 @default.
- W4353074429 hasBestOaLocation W43530744291 @default.
- W4353074429 hasConcept C105795698 @default.
- W4353074429 hasConcept C117568660 @default.
- W4353074429 hasConcept C126322002 @default.
- W4353074429 hasConcept C134018914 @default.
- W4353074429 hasConcept C144024400 @default.
- W4353074429 hasConcept C149923435 @default.
- W4353074429 hasConcept C151956035 @default.
- W4353074429 hasConcept C2777180221 @default.
- W4353074429 hasConcept C2780580376 @default.
- W4353074429 hasConcept C2780668416 @default.
- W4353074429 hasConcept C2781249084 @default.
- W4353074429 hasConcept C2781308992 @default.
- W4353074429 hasConcept C2909862629 @default.
- W4353074429 hasConcept C33923547 @default.
- W4353074429 hasConcept C511355011 @default.
- W4353074429 hasConcept C544821477 @default.
- W4353074429 hasConcept C555293320 @default.
- W4353074429 hasConcept C71924100 @default.
- W4353074429 hasConcept C95057490 @default.
- W4353074429 hasConceptScore W4353074429C105795698 @default.
- W4353074429 hasConceptScore W4353074429C117568660 @default.
- W4353074429 hasConceptScore W4353074429C126322002 @default.
- W4353074429 hasConceptScore W4353074429C134018914 @default.
- W4353074429 hasConceptScore W4353074429C144024400 @default.
- W4353074429 hasConceptScore W4353074429C149923435 @default.
- W4353074429 hasConceptScore W4353074429C151956035 @default.
- W4353074429 hasConceptScore W4353074429C2777180221 @default.
- W4353074429 hasConceptScore W4353074429C2780580376 @default.
- W4353074429 hasConceptScore W4353074429C2780668416 @default.
- W4353074429 hasConceptScore W4353074429C2781249084 @default.
- W4353074429 hasConceptScore W4353074429C2781308992 @default.
- W4353074429 hasConceptScore W4353074429C2909862629 @default.
- W4353074429 hasConceptScore W4353074429C33923547 @default.
- W4353074429 hasConceptScore W4353074429C511355011 @default.
- W4353074429 hasConceptScore W4353074429C544821477 @default.
- W4353074429 hasConceptScore W4353074429C555293320 @default.
- W4353074429 hasConceptScore W4353074429C71924100 @default.
- W4353074429 hasConceptScore W4353074429C95057490 @default.
- W4353074429 hasLocation W43530744291 @default.
- W4353074429 hasLocation W43530744292 @default.
- W4353074429 hasLocation W43530744293 @default.
- W4353074429 hasOpenAccess W4353074429 @default.
- W4353074429 hasPrimaryLocation W43530744291 @default.
- W4353074429 hasRelatedWork W1510377764 @default.
- W4353074429 hasRelatedWork W2139452290 @default.
- W4353074429 hasRelatedWork W2277193729 @default.
- W4353074429 hasRelatedWork W2334715211 @default.
- W4353074429 hasRelatedWork W2494119046 @default.
- W4353074429 hasRelatedWork W2805857714 @default.
- W4353074429 hasRelatedWork W2808271763 @default.